Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a, Double-blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of IRL201104 in Adult Participants With Active Eosinophilic Esophagitis (EoE)

X
Trial Profile

A Phase 2a, Double-blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Safety, and Tolerability of IRL201104 in Adult Participants With Active Eosinophilic Esophagitis (EoE)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IRL 201104 (Primary)
  • Indications Eosinophilic oesophagitis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Revolo Biotherapeutics
  • Most Recent Events

    • 30 Jan 2024 According to a Revolo Biotherapeutics media release, Based on the results from RVLO 121-04, the company plans to initiate a Phase 2b trial of 1104 in 2024,which will evaluate higher dose levels of 1104 and a longer duration of therapy.
    • 30 Jan 2024 According to a Revolo Biotherapeutics media release, the company received Orphan Drug Designation from FDA to 1104 ,for eosinophilic esophagitis treatment.
    • 30 Jan 2024 According to a Revolo Biotherapeutics media release,Evan Dellon is a Principal Investigator for the Phase 2a clinical trial.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top